Soleno Therapeutics Files 8-K
Ticker: SLNO · Form: 8-K · Filed: 2024-11-26T00:00:00.000Z
Sentiment: neutral
Topics: financial-reporting, exhibits
TL;DR
SOLENO THERAPEUTICS FILED AN 8-K WITH FINANCIALS AND EXHIBITS.
AI Summary
On November 26, 2024, Soleno Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosure related to the company's financial status. No specific material events or transactions were detailed in the provided excerpt.
Why It Matters
This filing serves as a public record of Soleno Therapeutics' financial information and exhibits, which is important for investors and analysts to assess the company's financial health and compliance.
Risk Assessment
Risk Level: low — The filing appears to be a standard procedural disclosure of financial statements and exhibits, not indicating any immediate significant risks or opportunities.
Key Players & Entities
- SOLENO THERAPEUTICS INC (company) — Registrant
- 0001484565 (company) — Central Index Key
- 100 Marine Parkway, Suite 400 (company) — Business Address
- Redwood City, CA 94065 (company) — Business Address
- 650-213-8444 (company) — Business Phone
FAQ
What is the primary purpose of this 8-K filing by Soleno Therapeutics, Inc.?
The 8-K filing is primarily for reporting 'Other Events' and 'Financial Statements and Exhibits' as of November 26, 2024.
What is Soleno Therapeutics, Inc.'s state of incorporation?
Soleno Therapeutics, Inc. is incorporated in Delaware.
What is the IRS Employer Identification Number for Soleno Therapeutics, Inc.?
The IRS Employer Identification Number for Soleno Therapeutics, Inc. is 77-0523891.
What is the principal executive office address for Soleno Therapeutics, Inc.?
The principal executive office address is 100 Marine Parkway, Suite 400, Redwood City, CA 94065.
When was Soleno Therapeutics, Inc. formerly known as Capnia, Inc.?
The name change from Capnia, Inc. to Soleno Therapeutics, Inc. occurred on February 19, 2010.
Filing Stats: 452 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-11-26 08:46:31
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value SLNO NASDAQ Indicate by
Filing Documents
- d802129d8k.htm (8-K) — 23KB
- d802129dex991.htm (EX-99.1) — 9KB
- g802129dsp1.jpg (GRAPHIC) — 12KB
- 0001193125-24-265687.txt ( ) — 171KB
- slno-20241126.xsd (EX-101.SCH) — 3KB
- slno-20241126_lab.xml (EX-101.LAB) — 18KB
- slno-20241126_pre.xml (EX-101.PRE) — 11KB
- d802129d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SOLENO THERAPEUTICS, INC. Date: November 26, 2024 By: /s/ Anish Bhatnagar Anish Bhatnagar Chief Executive Officer